Imaging Agents for Inflammatory Components of Malignancy

恶性肿瘤炎症成分的显像剂

基本信息

  • 批准号:
    10226210
  • 负责人:
  • 金额:
    $ 25.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-15 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

SUMMARY FOR TR&D 3 TR&D 3 of the BTRC will develop imaging agents to detect inflammation and immunity, with a focus on small molecule PET agents to monitor immunotherapy, an increasing medical need. Inflammation has long been recognized as a promoter of tumor growth. More recently, harnessing innate and adaptive immunity to treat cancer through immune checkpoint inhibition and vaccines has captivated the community of cancer researchers and clinicians alike. We will develop and disseminate agents that address two different aspects of cancer and its relationships to inflammation and immunity, namely, checkpoint inhibition and complement. The immune checkpoint protein programmed death-ligand 1 (PD-L1) and its receptor PD-1 are preferred targets for cancer immunotherapy. PD-L1 is expressed by a variety of tumors, and its over-expression is induced in tumor cells to adapt to tumor infiltrating cytotoxic T cells. PD-L1 immunohistochemistry (IHC) is the best predictive biomarker for therapeutic monitoring of PD-L1/PD-1 targeted therapies. However, PD-L1 IHC is fraught with use of discordant antibodies, intra- and inter-tumoral heterogeneity of expression as well as limited bio-specimen availability such that we believe non-invasive imaging can help. Furthermore, despite the promise of immune checkpoint therapy, the majority of patients do not respond for reasons unclear. The complement system is central to recruiting inflammatory cells and promoting release of factors that can promote tumor growth and progression, confounding immunotherapy. We will synthesize, validate and disseminate agents targeting PD-L1 (Aim 1) and complement receptors C3aR and C5aR (Aim 2), which are bound by their cognate tumor-promoting anaphylatoxins. In Aim 3 we will validate – with correlation to post-imaging surgical tissue – a current BTRC lead PD-L1 imaging agent in patients undergoing immunotherapy for pancreas cancer through support from the Bloomberg-Kimmel Institute for Immunotherapy. Once validated in this ultimate fashion we will be confident to disseminate that agent for human studies elsewhere. TR&D 3 will also serve as the Clinical Validation Core, a hub that will disseminate not only valuable new human agents as noted above, but will also provide precursor and standard for other agents, allow cross-referencing of BTRC INDs and provide analysis to meet the evolving needs of the driving Collaborative Projects and service recipients.
研发总结3 BTRC的研发3将开发用于检测炎症和免疫的显像剂,重点是小分子 用于监测免疫治疗的分子PET试剂,日益增长的医疗需求。长期以来,炎症一直是 被公认为是肿瘤生长的促进剂。最近,利用先天和获得性免疫来治疗 通过免疫检查点抑制和疫苗的癌症已经吸引了癌症研究人员的社区 和临床医生一样。我们将开发和传播针对癌症和其两个不同方面的药物 与炎症和免疫的关系,即检查点抑制和补体。免疫者 检查点蛋白程序性死亡配体1及其受体PD-1是肿瘤的首选靶点 免疫疗法。PD-L1在多种肿瘤中均有表达,其过表达可诱导肿瘤细胞 适应肿瘤浸润性细胞毒性T细胞。PD-L1免疫组织化学(IHC)是最好的预测生物标志物 用于PD-L1/PD-1靶向治疗的治疗监测。然而,PD-L1 IHC充满了对 不一致的抗体、瘤内和瘤间表达的异质性以及有限的生物标本 可用性使我们相信非侵入性成像可以提供帮助。此外,尽管有免疫的承诺 在检查点疗法中,大多数患者因不明原因而没有反应。补语系统是 募集炎性细胞和促进释放可促进肿瘤生长和 进展,混淆免疫疗法。我们将合成、验证和传播针对PD-L1的药物 (Aim 1)和补体受体C3aR和C5aR(Aim 2),它们由它们的同源促肿瘤作用结合 过敏毒素。在目标3中,我们将验证-与成像后手术组织相关-当前的BTRC导联 PD-L1显像剂在胰腺癌免疫治疗患者中的应用 彭博-基梅尔免疫疗法研究所。一旦以这种终极方式进行验证,我们将有信心 将这种用于人体研究的媒介传播到其他地方。研发3也将作为临床验证核心,一个 中心不仅将传播如上所述的有价值的新的人类媒介,而且还将提供前体 和其他代理的标准,允许交叉引用BTRC IND,并提供分析以满足不断发展的 推动协作项目和服务接受者的需求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN G POMPER其他文献

MARTIN G POMPER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN G POMPER', 18)}}的其他基金

Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
早期前列腺癌肿瘤微环境的转化成像生物标志物
  • 批准号:
    10698133
  • 财政年份:
    2022
  • 资助金额:
    $ 25.79万
  • 项目类别:
Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
早期前列腺癌肿瘤微环境的转化成像生物标志物
  • 批准号:
    10518916
  • 财政年份:
    2022
  • 资助金额:
    $ 25.79万
  • 项目类别:
Resource for Molecular Imaging Agents in Precision Medicine
精准医学分子成像剂资源
  • 批准号:
    10226206
  • 财政年份:
    2017
  • 资助金额:
    $ 25.79万
  • 项目类别:
Administration - Resource for Molecular Imaging Agents in Precision Medicine
管理 - 精准医学中分子成像剂的资源
  • 批准号:
    10226207
  • 财政年份:
    2017
  • 资助金额:
    $ 25.79万
  • 项目类别:
Training/Dissemination - Resource for Molecular Imaging Agents in Precision Medicine
培训/传播 - 精准医学分子成像剂资源
  • 批准号:
    10226214
  • 财政年份:
    2017
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    10594010
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    10411890
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    9886363
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    8671057
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:
Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
  • 批准号:
    10092113
  • 财政年份:
    2014
  • 资助金额:
    $ 25.79万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 25.79万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了